The groundbreaking rise of Viagra has firmly established as a example of pharmaceutical success, yet its position within the broader sector now raises questions about long-term gains. Alternative versions are diminishing exclusivity , causing worries that investing in companies heavily reliant to Viagra's former influence could be a dangerous decis